8-K: UFP Technologies Reports Record Q2, Driven by MedTech

UFP Technologies announced record second-quarter 2025 financial results, with significant growth in sales and net income, primarily fueled by strategic acquisitions and strong performance in its MedTech segment.

Summary

• Net sales for the second quarter ended June 30, 2025, increased 37.2% to $151.2 million, up from $110.2 million in Q2 2024.
• Net income for Q2 2025 rose to $17.2 million, or $2.21 per diluted common share, compared to $13.6 million, or $1.75 per diluted common share, in Q2 2024.
• Adjusted earnings per diluted common share outstanding grew 27% to $2.50.
• Sales to the medical market increased 46.0% to $139.3 million in Q2 2025, while non-medical sales decreased 19.8% to $11.8 million.
• Organic sales growth for the three-month period was 4.9%.
• Gross margin decreased to 28.8% in Q2 2025 from 30.0% in Q2 2024, impacted by approximately $1.2 million in incremental labor costs at the AJR facility due to workforce turnover related to E-Verify protocols.
• Two acquisitions were completed during Q2 2025: Universal Plastics & Engineering (UNIPEC) and Techno Plastics Industries (TPI), expanding capabilities in specialty film components and thermoplastic molding for medical devices.
• Progress continues on expansion plans in Santiago and La Romana, Dominican Republic, to support growth in safe patient handling and robotic-assisted surgery markets.

Sentiment

Score: 8

Explanation: The company reported record Q2 results with substantial growth in sales, net income, and EPS, primarily driven by strategic acquisitions and strong organic growth in the high-priority MedTech segment. While gross margins were slightly impacted by temporary labor inefficiencies, management has a clear plan for resolution, and the overall outlook remains highly positive with a strong growth pipeline.

Positives

• Achieved record second-quarter financial results.
• Reported substantial sales growth of 37.2% in Q2 2025 to $151.2 million.
• Net income increased by 26.5% to $17.2 million in Q2 2025.
• Diluted EPS grew by 26.3% to $2.21, with adjusted diluted EPS up 27% to $2.50.
• Medical market sales surged by 46.0% to $139.3 million, demonstrating strong demand in the core business segment.
• Maintained positive organic sales growth of 4.9% in Q2 2025.
• Successfully completed two strategic acquisitions (UNIPEC and TPI) that expand capabilities in key medical device manufacturing areas.
• Continued progress on facility expansions in the Dominican Republic to accommodate anticipated growth in high-demand medical markets.
• Management reports a strong and growing pipeline of new growth opportunities, both internal and through acquisitions.
• Selling, general and administrative expenses (SG&A) as a percentage of sales decreased to 12.4% in Q2 2025 from 12.6% in Q2 2024.

Negatives

• Gross profit margin decreased to 28.8% in Q2 2025 from 30.0% in Q2 2024.
• Gross margins were negatively impacted by approximately $1.2 million in incremental labor costs at the AJR facility.
• The labor cost impact was due to workforce turnover related to post-acquisition E-Verify protocols.
• Non-medical sales declined by 19.8% to $11.8 million in Q2 2025.
• Q3 is anticipated to be the low point for labor inefficiencies at the AJR facility.

Risks

• General ability to execute business plans.
• Industry conditions, including fluctuations in supply, demand, and prices for products and services due, in part, to inflation.
• Governmental regulations and/or sanctions affecting the import and export of products, including global trade barriers, additional taxes, tariff increases, cash repatriation restrictions, retaliations, and boycotts.
• Domestic, regional, and global political risks and uncertainties.
• Risks associated with the use of artificial intelligence technologies by the company or third parties.
• Risks related to indebtedness and compliance with covenants in financing arrangements, and the sufficiency of available financing.
• Risks relating to delayed payments by customers and the potential for reduced or canceled orders.
• Risks associated with customer concentration, particularly reliance on two largest customers, including Intuitive Surgical SARL.
• Risk that Intuitive Surgical SARL may decide to manufacture products itself or obtain them from other suppliers.
• Risk of not achieving expected rebates under applicable supply agreements.
• Risks relating to the ability to maintain or increase production at profitable levels.
• Risks relating to disruptions and delays in the supply chain or labor force.
• Risks associated with identifying suitable acquisition candidates, successful execution of acquisition transactions, integration of acquired companies, value realization from acquisitions, and financing of such acquisitions.

Future Outlook

Management anticipates that the third quarter will represent the low point for labor inefficiencies at the AJR facility, with gradual improvement expected to begin in the fourth quarter. The company plans to continue progress with its expansion initiatives in Santiago and La Romana, Dominican Republic, to support future growth in the safe patient handling and robotic-assisted surgery markets. A strong and growing pipeline of new growth opportunities, both internal and through acquisitions, is reported, leading to continued excitement about the company's future.

Management Comments

• "I am very pleased with our Q2 results."
• "Sales grew 37%, driven by strong contributions from our 2024 acquisitions combined with 5% organic growth."
• "Our MedTech business grew 46% while our Advanced Components business declined 20%."
• "Adjusted operating income and adjusted net income grew 35% and 27%, respectively."
• "Gross margins were 28.8% despite being impacted by approximately $1.2 million in incremental labor costs at our AJR facility. This was due to recent turnover in the workforce related to our post-acquisition review of US employment eligibility through E-Verify protocols."
• "We have successfully recruited legally eligible replacement associates and anticipate that Q3 will be the low point of labor inefficiencies, with gradual improvement beginning in the fourth quarter."
• "We completed two acquisitions during our second quarter: Universal Plastics & Engineering (UNIPEC) and Techno Plastics Industries (TPI). These will expand our capabilities in tight-tolerance specialty film components and in thermoplastic molding for the medical device market."
• "In addition, we continued to make progress with our expansion plans in Santiago and La Romana, Dominican Republic, to accommodate further anticipated growth in the safe patient handling and robotic-assisted surgery markets."
• "Our pipeline of new growth opportunities—both internal and via acquisition—is strong and growing."
• "For these reasons and more, we remain excited about our future."

Industry Context

UFP Technologies operates as a crucial contract development and manufacturing organization (CDMO) within the medical device supply chain, specializing in single-use and single-patient devices. The company's strong Q2 performance, particularly the 46% growth in its MedTech business, aligns with the broader industry trend of increasing demand for specialized medical components and outsourcing by top medical device manufacturers. The strategic acquisitions of UNIPEC and TPI further enhance its capabilities in high-growth areas like specialty film components and thermoplastic molding for medical applications, reflecting a strategic alignment with evolving medical technology needs. The decline in non-medical sales suggests a focused pivot towards the more lucrative and expanding medical sector, which is driven by advancements in minimally invasive surgery, infection prevention, and robotic-assisted procedures.

Stakeholder Impact

• Shareholders are positively impacted by record financial performance, increased net income and EPS, strategic acquisitions, and a strong growth outlook.
• Employees at the AJR facility experienced turnover due to E-Verify protocols, but new legally eligible associates are being recruited, and company expansion plans may create new job opportunities.
• Customers, particularly medical device manufacturers, benefit from expanded capabilities through recent acquisitions and facility expansions, suggesting improved service and increased capacity.
• Suppliers may see increased demand for their products and services due to the company's growth and expansion initiatives.
• Creditors are positively impacted by the company's strong financial performance, which indicates robust repayment capacity and financial health.

Next Steps

• Recruit legally eligible replacement associates for the AJR facility.
• Address labor inefficiencies at the AJR facility, with anticipated gradual improvement starting in Q4.
• Continue progress with expansion plans in Santiago and La Romana, Dominican Republic.
• Pursue new growth opportunities, both internal and via acquisition.
• Host a conference call on August 5, 2025, at 8:30 AM Eastern time to discuss results.

Key Dates

Recommendation

UFP Technologies delivered exceptional Q2 2025 results, demonstrating robust growth across key financial metrics including sales, net income, and EPS, significantly outperforming the prior year. The strategic focus on the high-growth MedTech sector, bolstered by successful acquisitions and organic expansion, positions the company favorably. While a temporary labor issue impacted gross margins, management has a clear plan for resolution, and the overall trajectory remains highly positive with a strong pipeline of future opportunities. This strong performance and clear growth strategy make UFPT an attractive investment.

Keywords

Medical devices, Contract manufacturing, CDMO, Single-use medical devices, Single-patient medical devices, UFP Technologies, UFPT, MedTech, Thermoplastic molding, Specialty film components, Robotic-assisted surgery, Safe patient handling, Earnings report, Financial results, Acquisitions